A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 47/48 (2006.01) A61K 31/44 (2006.01) A61K 31/445 (2006.01) A61K 31/53 (2006.01) A61K 31/70 (2006.01) A61K 31/704 (2006.01) A61K 31/7068 (2006.01) A61K 39/395 (2006.01) A61K 45/06 (2006.01) A61P 35/00 (2006.01) A61P 35/02 (2006.01)
Patent
CA 2504611
Methods of treatment and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia, and myelodysplastic syndrome. The methods of treatment and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analog. Preferred methods of treatment and pharmaceutical combinations employ gemtuzumab ozogamicin, daunorubicin, and cytarabine.
L'invention porte sur des méthodes thérapeutiques et des combinaisons pharmaceutiques de traitement de leucémies aiguës telles que la leucémie myélogène aiguë ou le syndrome myélodysplasique, utilisant un conjugué cytotoxique anti-CD33 associé à au moins un composé choisi parmi l'anthracycline, ou un analogue de nucléoside de la pyrimidine ou de la purine. Les méthodes thérapeutiques et combinaisons pharmaceutiques préférées utilisent la gemtuzumab ozogamicine, la daunorubicine, et la cytarabine.
Berger Mark
Feingold Jay Marshall
Leopold Lance H.
Sherman Matthew L.
Torys Llp
Wyeth
LandOfFree
Combination therapy for the treatment of acute leukemia and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy for the treatment of acute leukemia and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for the treatment of acute leukemia and... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1982717